Novartis withdraws marketing application for Ruvise
LONDON (Reuters) - Swiss drugmaker Novartis has withdrawn a marketing application for its drug Ruvise, designed to treat arterial hypertension, the European Medicines Agency (EMA) said on Thursday.
The drug, known generically imatinib mesilate, was intended for use in adults as add-on therapy for the treatment of pulmonary arterial hypertension (PAH), the drug regulator said in a statement.
EMA reported that Novartis had said that the withdrawal was because it requires additional data to address the regulator's questions relating to its benefit-risk assessment.
The data would not be available within the timeframe allowed in the centralized procedure, it said.
(Reporting by Kate Kelland; Editing by David Goodman)
- Tweet this
- Share this
- Digg this
- Iran to push for Saudi oil output cut at OPEC - Mehr news agency
- Tesla says in talks with BMW over car batteries, parts
- Aviva, Friends Life 5.6 billion pound merger plan makes sense - investors
- Exclusive - China ready to cut rates again on fears of deflation: sources
- Aviva shares fall, Friends Life jumps seven percent on merger news